Sanofi’s FREVIVA Study is looking for people with non-relapsing secondary progressive multiple sclerosis (nrSPMS) to take part. The goal of this Phase 3 clinical trial is to demonstrate the efficacy and safety of frexalimab compared to placebo in participants with nrSPMS to delay disability progression.